VirtualBrainCloud · Project

Cloud Brain Simulation Platform for Personalized Alzheimer's Diagnosis and Treatment

healthTestedTRL 5

virtualbraincloud-2020.eu

Imagine having a digital twin of a patient's brain that doctors could use to predict how Alzheimer's will progress — and which treatment will work best for that specific person. That's what this project built: a cloud-based simulation platform that combines brain imaging data with molecular-level biology to create personalized brain models. Think of it like a flight simulator, but for neurologists — they can test treatment strategies on the virtual brain before trying them on the patient. The platform connects data from multiple European brain research initiatives and runs on high-performance cloud computing.

By the numbers

777.81 billion Euro

Annual worldwide cost of Alzheimer's dementia in 2015

7.41 trillion Euro

Projected annual worldwide cost of Alzheimer's by 2050

$7.9 trillion

Potential savings from early diagnosis by 2050 in the US alone

Consortium partners across 10 countries

Total project deliverables produced

SMEs involved in the consortium

The business problem

What needed solving

Alzheimer's disease costs the world 777.81 billion Euro annually and treatment remains one-size-fits-all because every patient's brain deteriorates differently. Clinicians and pharma companies lack tools to simulate individual disease progression and test personalized treatment strategies before applying them to real patients.

The solution

What was built

A fully integrated and validated cloud-based brain simulation platform (VBC) that creates personalized brain models for neurodegenerative disease diagnostics. Concrete outputs include a health & lifestyle recommendation system implemented in a patient interface app, a 3D brain viewer with personalized coordinates, a text mining workflow for extracting cause-and-effect relationships from medical literature, and a validated clinical use case for scientists and clinicians.

Audience

Who needs this

Pharmaceutical companies with Alzheimer's or neurodegeneration drug pipelinesHealth IT vendors building clinical decision support productsHospital networks and neurology departments managing dementia patient populationsBrain imaging and diagnostics device manufacturersInsurance companies modeling long-term care costs for neurodegeneration

Business applications

Who can put this to work

Pharmaceutical & Drug Development

enterprise

Target: Pharma companies developing treatments for neurodegenerative diseases

If you are a pharmaceutical company investing in Alzheimer's drug development — this project built a cloud-based brain simulation platform that can identify therapeutic targets by modeling disease progression at the individual patient level. The platform was evaluated specifically for therapeutic target discovery. With worldwide Alzheimer's costs projected to reach 7.41 trillion Euro by 2050, tools that accelerate drug development pipelines have massive commercial value.

Digital Health & Clinical Software

mid-size

Target: Health IT companies building clinical decision support systems

If you are a health IT company looking to integrate advanced diagnostic tools into clinical workflows — this project delivered a fully integrated and validated cloud platform with a patient-facing recommendation app. The system includes a 3D brain viewer, personalized simulations, and health & lifestyle recommendations. It connects to existing European computing infrastructure (PRACE) and complies with EU data governance standards.

Healthcare & Hospital Networks

enterprise

Target: Hospital groups and neurology clinics managing large Alzheimer's patient populations

If you are a hospital network or neurology clinic dealing with the challenge of personalizing care for Alzheimer's patients — this platform provides a decision support system that generates individualized diagnostics using the patient's own brain data. Early diagnosis alone could save up to $7.9 trillion in medical and care costs by 2050 in the US. The validated use case was designed specifically for clinicians to plan refined clinical studies and treatment strategies.

Frequently asked

Quick answers

What would it cost to license or access this platform?

The project data does not include specific licensing costs or pricing models. The platform was built as a Research and Innovation Action (RIA), meaning it is publicly funded research. Interested companies should contact the coordinator at Charité Berlin to discuss access terms, potential licensing, or collaboration agreements.

Can this platform handle the scale of a large hospital network or pharma pipeline?

The platform was designed for cloud deployment and leverages EU PRACE high-performance computing infrastructure, which suggests it can scale beyond a single-site installation. The final VBC platform was fully integrated and validated with documentation of its functionalities. However, production-scale deployment for commercial healthcare settings would likely require additional engineering.

Who owns the intellectual property, and can we license it?

The consortium of 20 partners across 10 countries jointly developed this technology under EU Horizon 2020 rules. IP ownership is typically shared among contributing partners per the grant agreement. The coordinator at Charité - Universitätsmedizin Berlin would be the first contact point for licensing discussions.

Does this meet EU healthcare data regulations?

The project specifically addressed legal and ethical matters by interacting with EU initiatives including European Open Science Cloud (EOSC), cloud4health, Alzheimer's Europe patient organizations, and ELIXIR for research data management. This suggests strong attention to GDPR and healthcare data governance, though specific certifications would need to be confirmed with the consortium.

How long before this could be used in a real clinical setting?

The project ran from December 2018 to May 2023 and delivered a validated use case of the brain simulation platform usable by scientists and clinicians. A health & lifestyle recommendation system was implemented in a patient interface app. However, moving from validated research platform to certified clinical tool typically requires additional regulatory steps (e.g., CE marking as a medical device).

Can this integrate with our existing hospital IT systems?

The platform was built as a cloud-based system with a semantically enhanced multi-viewer and 3D brain visualization. It was designed to integrate data from multiple sources including The Virtual Brain and IMI-EPAD initiatives. Integration with specific hospital EHR systems would likely require custom connector work, but the cloud architecture and standards-based approach are favorable starting points.

Consortium

Who built it

The VirtualBrainCloud consortium brings together 20 partners from 10 countries (AT, DE, ES, FI, FR, IT, LU, NL, RO, UK), led by Charité - Universitätsmedizin Berlin, one of Europe's largest university hospitals. The consortium is research-heavy with 8 universities and 8 research organizations, but includes 4 industry partners and 5 SMEs (20% industry ratio). This composition reflects the project's deep scientific roots in computational neuroscience while maintaining a pathway to commercial translation. The involvement of SMEs suggests some market-oriented thinking, though the balance tilts toward academic research rather than product development. For a business partner, the key value is access to a broad European network spanning clinical, computational, and regulatory expertise.

CHARITE - UNIVERSITAETSMEDIZIN BERLINCoordinator · DE
INSTITUT NATIONAL DE RECHERCHE EN INFORMATIQUE ET AUTOMATIQUEparticipant · FR
HELSINGIN YLIOPISTOparticipant · FI
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALEthirdparty · FR
FORSCHUNGSZENTRUM JULICH GMBHparticipant · DE
STICHTING RADBOUD UNIVERSITEITparticipant · NL
UNIVERSITAT WIENparticipant · AT
TP21 GMBHparticipant · DE
FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYAparticipant · ES
INSTITUT DU CERVEAU ET DE LA MOELLE EPINIEREparticipant · FR
EODYNE SYSTEMS SLparticipant · ES
UNIVERSIDAD COMPLUTENSE DE MADRIDparticipant · ES
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORDparticipant · UK
UNIVERSITE D'AIX MARSEILLEparticipant · FR
UNIVERSITA DEGLI STUDI DI GENOVAparticipant · IT
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRSthirdparty · FR
ALZHEIMER EUROPEparticipant · LU

How to reach the team

Charité - Universitätsmedizin Berlin, Germany — reach out to the project coordination office for licensing and collaboration inquiries

Order a report on this consortium See CHARITE - UNIVERSITAETSMEDIZIN BERLIN profile →

Next steps

Talk to the team behind this work.

Want to explore how this brain simulation platform could accelerate your Alzheimer's R&D pipeline or clinical diagnostics? SciTransfer can arrange a direct introduction to the research team.

Order a report on this topic More in Health & Biomedical